PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34790723-11 2021 Finally, in vitro study showed that BBR promoted intracellular cholesterol efflux, up-regulated LDLR and down-regulated PCSK9 expression via the ERK1/2 pathway in cultured HepG2 cells. Berberine 36-39 mitogen-activated protein kinase 3 Homo sapiens 145-151 35460012-6 2022 BBR inhibits the MEKK1 and MEK1/2, and thus suppresses the activation of their downstream ERK1/2. Berberine 0-3 mitogen-activated protein kinase 3 Homo sapiens 90-96 31139563-6 2019 In this study, we demonstrate that berberine significantly inhibits inflammatory cytokine Caspase-1 activation via ERK1/2 signaling and subsequent production of IL-1beta and IL-18 by glioma cells. Berberine 35-44 mitogen-activated protein kinase 3 Homo sapiens 115-121 31968208-5 2020 In this review, we have attempted to discuss the reported anti-inflammatory properties of berberine that function through several pathways such as, the NF-kappaB, ERK1/2 and p38 MAPK pathways which affect several pro-inflammatory cytokines in the pathophysiological processes involved in chronic respiratory diseases. Berberine 90-99 mitogen-activated protein kinase 3 Homo sapiens 163-169 30343043-0 2019 Antitumor effects of berberine against EGFR, ERK1/2, P38 and AKT in MDA-MB231 and MCF-7 breast cancer cells using molecular modelling and in vitro study. Berberine 21-30 mitogen-activated protein kinase 3 Homo sapiens 45-51 30343043-5 2019 The effects of berberine and lapatinib on MAPK and PI3K pathways in MDA-MB231 and MCF-7 cells were evaluated using immunoflorescence assays, and the amounts of phosphorylated kinases were compared to total kinases after treating with different concentrations of berberine. Berberine 15-24 mitogen-activated protein kinase 3 Homo sapiens 42-46 30343043-6 2019 RESULTS: Simulations showed berberine accurately interacted with EGFR, AKT, P38, and ERK1/2 active sites in silico (scores = -7.57 to -7.92 Kcal/mol) and decreased the levels of active forms of corresponding enzymes in both cell lines; however, berberine binding to p38 showed less stability. Berberine 28-37 mitogen-activated protein kinase 3 Homo sapiens 85-91 30343043-6 2019 RESULTS: Simulations showed berberine accurately interacted with EGFR, AKT, P38, and ERK1/2 active sites in silico (scores = -7.57 to -7.92 Kcal/mol) and decreased the levels of active forms of corresponding enzymes in both cell lines; however, berberine binding to p38 showed less stability. Berberine 245-254 mitogen-activated protein kinase 3 Homo sapiens 85-91 30343043-9 2019 The activity of EGFR, AKT, P38, and ERK1/2 were affected by berberine; however, berberine dramatically reduced EGFR and AKT phosphorylation. Berberine 60-69 mitogen-activated protein kinase 3 Homo sapiens 36-42 28566619-7 2017 The inhibition was largely attributed to cell cycle arrest at the G1 phase through the reduction of cyclin D1, and cyclin E. Moreover, berberine could reduce the expression and activation of signal transducers and activator of transcription 3 (STAT3) and probably nuclear factor-kappaB (NF-kappaB) via suppression of extracellular signal-regulated kinase (ERK) 1/2 action. Berberine 135-144 mitogen-activated protein kinase 3 Homo sapiens 317-364 30104528-6 2018 Results from western blotting indicated that berberine inhibited the expression of MMP-1, MMP-13, E-cadherin, N-cadherin, RhoA, ROCK1, SOS-1, GRB2, Ras, p-ERK1/2, p-c-Jun, p-FAK, p-AKT, NF-kappaB, and uPA after 24 h of treatment, but increased the PKC and PI3K in A375.S2 cells. Berberine 45-54 mitogen-activated protein kinase 3 Homo sapiens 155-161 29604589-0 2018 Oncosis-like cell death is induced by berberine through ERK1/2-mediated impairment of mitochondrial aerobic respiration in gliomas. Berberine 38-47 mitogen-activated protein kinase 3 Homo sapiens 56-62 29604589-4 2018 We also found that berberine induced autophagy as a protective effect and decreased the oxygen consumption rate (OCR), which could inhibit mitochondrial aerobic respiration by repressing phosphorylated extracellular regulated protein kinases (p-ERK1/2). Berberine 19-28 mitogen-activated protein kinase 3 Homo sapiens 245-251 29604589-5 2018 Furthermore, the down-regulation of mitochondrial p-ERK1/2 by berberine inhibited aerobic respiration and led to glycolysis, an inefficient energy production pathway. Berberine 62-71 mitogen-activated protein kinase 3 Homo sapiens 52-58 29604589-6 2018 In addition, berberine reduced tumor growth and inhibited Ki-67 and p-ERK1/2 expression in vivo. Berberine 13-22 mitogen-activated protein kinase 3 Homo sapiens 70-76 29604589-7 2018 The results demonstrate that berberine, which represses aerobic oxidation in mitochondria and decreases their energy production efficiency, decreases metabolic activity by reducing ERK1/2 activity. Berberine 29-38 mitogen-activated protein kinase 3 Homo sapiens 181-187 29118901-9 2017 Taken together, our data suggested that BBR inhibited ox-LDL-induced HUVECs proliferation by decreasing the expression of PCNA, NF-kB and LOX-1 and suppressing the activation of PI3K/Akt, ERK1/2 and p38MAPK pathways, indicating a latent candidate for anti-atherosclerosis clinically. Berberine 40-43 mitogen-activated protein kinase 3 Homo sapiens 188-194 28190470-9 2017 Furthermore, berberine downregulates the phosphorylation of VEGFR2 and downstream signaling members (AKT and Erk1/2), which in turn downregulates the expression of MMP2 and MMP9. Berberine 13-22 mitogen-activated protein kinase 3 Homo sapiens 109-115 26503508-9 2015 Moreover, the phosphorylation of extracellular signal-regulated kinase (ERK1/2) and p38, components of the mitogen-activated protein kinase pathway that are associated with the expression of MMP and VEGF, was suppressed in FaDu cells treated with berberine for 24 h. Therefore, these data suggested that berberine exerted anticancer effects in FaDu cells through induction of apoptosis and suppression of migration. Berberine 247-256 mitogen-activated protein kinase 3 Homo sapiens 72-78 30204365-0 2016 [Study of Berberine on Attenuating PM2.5-Induced Vascular Endothelial Cells Injury by ERK1/2 Signal Pathway]. Berberine 10-19 mitogen-activated protein kinase 3 Homo sapiens 86-92 27092498-6 2016 Furthermore, berberine inactivated p38 and Erk1/2 signaling pathway in HCC cells. Berberine 13-22 mitogen-activated protein kinase 3 Homo sapiens 43-49 26503508-9 2015 Moreover, the phosphorylation of extracellular signal-regulated kinase (ERK1/2) and p38, components of the mitogen-activated protein kinase pathway that are associated with the expression of MMP and VEGF, was suppressed in FaDu cells treated with berberine for 24 h. Therefore, these data suggested that berberine exerted anticancer effects in FaDu cells through induction of apoptosis and suppression of migration. Berberine 304-313 mitogen-activated protein kinase 3 Homo sapiens 72-78 24508518-7 2014 Moreover, berberine significantly inhibited the upstream signaling of autophagy, such as the mammalian target of rapamycin (mTOR), extracellular signal-regulated kinase (ERK1/2), and p38 mitogen-activated protein kinase (MAPK) phosphorylation. Berberine 10-19 mitogen-activated protein kinase 3 Homo sapiens 170-176 26421434-8 2015 The hormetic effect and thereby the attenuated anticancer activity of chemotherapeutic drugs by berberine may attributable to the activated protective stress response in cancer cells triggered by berberine, as evidenced by up-regulated MAPK/ERK1/2 and PI3K/AKT signaling pathways. Berberine 96-105 mitogen-activated protein kinase 3 Homo sapiens 236-240 26421434-8 2015 The hormetic effect and thereby the attenuated anticancer activity of chemotherapeutic drugs by berberine may attributable to the activated protective stress response in cancer cells triggered by berberine, as evidenced by up-regulated MAPK/ERK1/2 and PI3K/AKT signaling pathways. Berberine 96-105 mitogen-activated protein kinase 3 Homo sapiens 241-247 26421434-8 2015 The hormetic effect and thereby the attenuated anticancer activity of chemotherapeutic drugs by berberine may attributable to the activated protective stress response in cancer cells triggered by berberine, as evidenced by up-regulated MAPK/ERK1/2 and PI3K/AKT signaling pathways. Berberine 196-205 mitogen-activated protein kinase 3 Homo sapiens 236-240 24508518-7 2014 Moreover, berberine significantly inhibited the upstream signaling of autophagy, such as the mammalian target of rapamycin (mTOR), extracellular signal-regulated kinase (ERK1/2), and p38 mitogen-activated protein kinase (MAPK) phosphorylation. Berberine 10-19 mitogen-activated protein kinase 3 Homo sapiens 221-225 24508518-8 2014 We conclude that berberine could attenuate left ventricular remodeling and cardiomyocyte apoptosis through an autophagy-dependent mechanism in a rat model of cardiac hypertrophy, which is, at least in part, associated with enhanced autophagy through inhibition of mTOR, p38 and ERK1/2 MAPK signaling pathways. Berberine 17-26 mitogen-activated protein kinase 3 Homo sapiens 285-289 21747769-9 2011 However, berberine pre-treatment prevented stimulation of p42/p44 MAPK by epidermal growth factor. Berberine 9-18 mitogen-activated protein kinase 3 Homo sapiens 62-70 21747769-10 2011 The inhibitory effect of berberine on Cl(-) secretion was partially blocked by HBDDE (~65%), an inhibitor of PKCalpha and to a smaller extent by inhibition of p38 MAPK with SB202190 (~15%). Berberine 25-34 mitogen-activated protein kinase 3 Homo sapiens 163-167 18710638-1 2008 BACKGROUND: This study investigated the inhibitory effect of berberine (BBR) on lipopolysaccharide (LPS) induced cyclooxygenase-2 (COX-2) expression via the mitogen activated protein kinase (MAPK) signalling cascade pathways in human peripheral blood monocytes (PBMC). Berberine 61-70 mitogen-activated protein kinase 3 Homo sapiens 191-195 18710638-6 2008 With BBR treatment for 6, 12 or 24 hours at three doses, ERK1/2 protein expression was significantly inhibited. Berberine 5-8 mitogen-activated protein kinase 3 Homo sapiens 57-63 18710638-10 2008 CONCLUSIONS: Berberine inhibits COX-2 expression via the ERK1/2 signalling pathway and, possibly, at a high dosage via the JNK pathway. Berberine 13-22 mitogen-activated protein kinase 3 Homo sapiens 57-63 17292731-7 2007 Berberine activated extracellular signal-regulated kinase (ERK) 1/2, but PD98059, an ERK kinase inhibitor, only decreased berberine-stimulated glucose uptake by 32%. Berberine 0-9 mitogen-activated protein kinase 3 Homo sapiens 20-67